Vestec, Czech Republic – July 24, 2025 – DIANA Biotechnologies is pleased to announce the successful completion of its research project focused on the development of a new assay for profiling inhibitors of cyclin-dependent kinases (CDKs). The project, titled "DIANA panel for testing the selectivity of inhibitors of clinically relevant kinases and its application in the drug discovery market", received the highest possible evaluation during its final review by the Technology Agency of the Czech Republic (TA ČR). This recognition highlights the significance of our work in enhancing tools for kinase inhibitor screening, a key step in the development of targeted therapies.

CDKs: One of the key targets in cancer treatement

Cyclin-dependent kinases (CDKs) are a family of enzymes that play a critical role in regulating the cell cycle, transcription, and other essential cellular processes. They serve as molecular switches that coordinate cell division and gene expression, and their proper function is vital for cellular homeostasis. Dysregulation of CDK activity has been strongly associated with various cancers and other proliferative disorders, making them important targets in the field of therapeutic drug development. Understanding and accurately measuring CDK inhibitor activity is therefore critical to advancing modern oncology treatments.

The outcome of the project is our DIANA CDK Panel — an innovative profiling platform that allows researchers to comprehensively test the selectivity and potency of CDK inhibitors across a broad range of CDK isoforms. This highly sensitive and reproducible assay enables accurate evaluation of inhibitor binding affinities, providing valuable insights during early drug development. The panel currently includes multiple CDK family members, supporting both basic research and pharmaceutical development of targeted cancer therapies.

Further information about the DIANA CDK Panel can be found here.

We are proud of our team’s achievement and honored by the recognition from TA ČR. This success reaffirms our commitment to advancing precision tools for modern drug discovery and to contributing innovative solutions for unmet medical needs.

Media contact:

Petr Kašík

E-mail: [email protected]

About DIANA Biotechnologies

DIANA Biotechnologies, a.s. is a Czech biotechnology company with strong in-house research and development. The company was founded in 2018 with the aim to develop applications of the patented DIANA technology in diagnostics and drug development. However, the company's portfolio is now significantly broader. It is currently targeting global markets in three main areas: 1) development and production of PCR products for diagnostics and life science, 2) development of proprietary original low molecular weight drugs and provision of services to the pharmaceutical sector, and 3) development of antibodies for diagnostics and therapeutics. In the field of molecular diagnostics, the company has become the largest Czech manufacturer of PCR tests for COVID-19 and other viral diseases and is now making its mark abroad thanks to its innovations in PCR diagnostics. The company is built on a team of top scientists with unique expertise in molecular biology, biochemistry, organic and medicinal chemistry, pharmacology and laboratory automation. DIANA Biotechnologies aims to become a multinational biotechnology company developing its own original diagnostics and pharmaceuticals.